Chargement de l’entreprise
Just reported
From Arbutus Biopharma's results release of 10 novembre 2026; its quarterly report has since been filed.
Actual
299K $US
-43 % y/y
-71 % q/q
Guided
—
No guide given
Actual
0,30 $US
Guided
—
No guide given
Actual
-10,5M $US
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Arbutus Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.48B $USA+
EXELExelixis, Inc.17,3B $USA+
JAZZJazz Pharmaceuticals plc15,9B $USA
HALOHalozyme Therapeutics, Inc.11,6B $USA+
TECHBIO-Techne Corp11,4B $USA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now AConstruit à partir des documents déposés par Arbutus Biopharma Corp. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
Grade D+
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 41 de l’historique des notes de Arbutus Biopharma Corp.. Les 39 autres remontent jusqu’à novembre 2016.
